Navigation Links
Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
Date:4/17/2008

$1,736 $2,539

Receivables 2,096 2,026

Inventories 2,536 2,334

Other current assets 645 656

--------------------------------

Total current assets 7,013 7,555

--------------------------------

Property, plant and equipment, net 4,633 4,487

Other long-term assets 3,326 3,252

-------------------------------------------------------------------------

Total assets $14,972 $15,294

=========================================================================

Liabilities and Shareholders' Equity

------------------------------------

Short-term debt $141 $425

Other current liabilities 3,095 3,387

Long-term debt 2,731 2,664

Other long-term liabilities 2,008 1,902

Shareholders' equity 6,997 6,916

-------------------------------------------------------------------------

Total liabilities and shareholders'

equity $14,972 $15,294

=========================================================================

BAXTER INTERNATIONAL INC.

Cash Flows from Operations and Changes in Net Debt

(unaudited)

($ in millions)

Cash Flows from Operations

(Brackets denote cash outflows)


'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
2. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
3. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
4. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
7. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
8. Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit
9. Baxter International Fourth Quarter 2007 Financial Results Conference Call
10. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
11. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... more than EUR 1.022 billion in 2013; while production volume reached close to ... leading producing country with a share of 75.5% of the region’s total aluminium ...
(Date:7/28/2015)... -- Deerfield Management Company, L.P. today announced the launch ... invest in groundbreaking advancements in science that may lead ... diseases. The venture capital fund will also back new ... improve the way healthcare is delivered to patients. ... funds in the sector, will donate all profits not ...
(Date:7/28/2015)... July 28, 2015 BioStructures, LLC, a ... hit a milestone of 4,000 implantations of Signafuse® ... cleared in early 2014 as a bone void ... fusion procedures.  This is a distinguished status among ... 6% of new synthetic products have received clearance ...
(Date:7/28/2015)... ZIONA, Israel , July ... (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing its ... today announced that Shomrat Shurtz has been appointed ... 2015.      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ... 25 years of experience in marketing, regulatory and ...
Breaking Biology Technology:EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Revolutionary Bone Graft Exceeds Expectations 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 2
... Vasogen Inc. (NASDAQ: VSGN ; TSX:VAS) today reported the ... 2009. All dollar amounts referenced herein are in Canadian dollars ... and cash equivalents totaled $7.3 million, compared with $8.6 million ... for the three months ended February 28, 2009 of $1.9 ...
... Wash., April 13 BioLife Solutions, Inc.,(OTC ... marketer of proprietary,cGMP hypothermic storage and cryopreservation ... announced that the Rutgers University ... university-based biologics repository,has adopted the Company,s CryoStor ...
... Cell Biosciences, Inc., a provider of nanoproteomic analysis systems ... a landmark study by a research team from ... Felsher, Associate Professor of Oncology, was senior author on ... serial analysis of oncoprotein activation in clinical samples", appeared ...
Cached Biology Technology:Vasogen Announces First Quarter 2009 Results 2Vasogen Announces First Quarter 2009 Results 3Vasogen Announces First Quarter 2009 Results 4Vasogen Announces First Quarter 2009 Results 5Vasogen Announces First Quarter 2009 Results 6Vasogen Announces First Quarter 2009 Results 7Vasogen Announces First Quarter 2009 Results 8Vasogen Announces First Quarter 2009 Results 9Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media 2Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media 3Cell Biosciences Announces Publication in Nature Medicine 2
(Date:7/23/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ) ... Outlook of the Biometrics Industry 2015 " ... global biometrics market is likely to witness significant ... to the uptake of multiple technologies available. The ... the growth of biometrics in existing applications as ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... department of radiology at Boston University School of Medicine ... Challenges Explorations (GCE) winner, an initiative funded by the ... third year radiology resident at BMC, and Ducksoo Kim, ... the vascular and interventional radiology fellowship at BMC, will ...
... impairment is a transitional stage between normal aging ... this transformation have yet to be studied. Dr. ... Technology, China constructed brain networks using resting-state functional ... (normal controls, patients with early mild cognitive impairment, ...
... with researchers at the University of Quebec at Montreal, ... of pharmaceutical drugs to treat diseases such as cystic ... percentage of pharmaceutical drugs target ion channels, which are ... pivotal role in these serious disorders and that are ...
Cached Biology News:BUSM/BMC receives Grand Challenges Explorations grant to develop next generation condom 2BUSM/BMC receives Grand Challenges Explorations grant to develop next generation condom 3New technique for testing drugs to treat cystic fibrosis and epilepsy 2
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
... Anti-acetyl-Histone H3 (Lys 4) ... sequence ...RT[ Ac K]Q... in which [ ... of human histone H3 ... Molecular Weight: Mr ~17kDa ...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
b-Catenin (pSer675), phospho-specific...
Biology Products: